Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial.

Front Mol Neurosci · 2022 · PMC9205636 · PMID 35721320

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

an increasing trendP = 0.069so close (0.05 < p ≤ 0.1)

a decreasing trendP = 0.086so close (0.05 < p ≤ 0.1)

It should be notable that the PRL of the metformin group showed a decreasing trend (from 1737.360 ± 626.918 to 1618.625 ± 640.865, t = 1.759, P = 0.086), while that of the placebo group showed an increasing trend (from 2676.470 ± 1269.234 to 2860.933 ± 1317.376, t = 1.866, P = 0.069).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.